Gene therapy specialist Orchard Therapeutics (Nasdaq: ORTX) has licensed technology from the UK’s GlaxoSmithKline (LSE: GSK), lifting its shares by a tenth.
Orchard will make use of GSK’s proprietary lentiviral stable cell line technology (LV-SCLT) to develop two investigational hematopoietic stem cell gene therapies.
The firm is developing OTL-103 for Wiskott Aldrich syndrome and OTL-300 for transfusion-dependent beta thalassemia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze